TY - JOUR AB - INTRODUCTION: Genetic factors play a significant role in the development of leukemia. The overexpression of MDM2 is associated with the progression of certain leukemias. This meta-analysis investigates the relationship between the MDM2 SNP 309T>G and various forms of leukemia across global populations. METHODS: A comprehensive literature search was conducted to retrieve genotyping data from twenty casecontrol studies related to MDM2 SNP 309T>G polymorphism and leukemia. A random-effects model was used to calculate the pooled odds ratio (OR) and 95% confidence interval (95% CI) for the association analysis. MetaGenyo software was utilized to conduct statistical analyses in this meta-analysis. RESULTS: The findings indicate a significant association between MDM2 309 SNPT>G polymorphism and leukemia in Asian and Caucasian populations. Additionally, this polymorphism is associated with an increased risk of Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML), implying that MDM2 may play a role in the pathogenesis of these specific forms of leukemia. CONCLUSION: This meta-analysis suggests that MDM2 may represent a susceptibility gene for leukemia risk. AU - Naik, T.* AU - Verma, H.K. AU - Mulkalwar, M.* AU - Mishra, D.* AU - Bhaskar, L.* C1 - 75237 C2 - 57870 CY - Executive Ste Y-2, Po Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates TI - Comprehensive meta-analysis on the impact of the MDM2 SNP 309 T>G gene variant in leukemia susceptibility. JO - Curr. Pharm. Des. PB - Bentham Science Publ Ltd PY - 2025 SN - 1381-6128 ER - TY - JOUR AB - BACKGROUND: Nanopharmaceuticals serve as emerging forms of modern medicines which include nanomedicines, nanosimilars, nanotheranostics, nanodevices and many more. In last two decades, a large number of nano-based products has reached to the market and are being used clinically. OBJECTIVES: Unlike, conventional pharmaceutical products, nanopharmaceuticals behave differently both in vitro and in vivo and therefore, development of their generic versions needs special attention to replicate the similar drug release pattern leading to the identical therapeutic outcome. Further, drug-device combinations and 3D products are latest advancements in precise medicine delivery and development. METHODS: The regulatory guidelines for these products are being framed at many stages by various regulatory agencies like USFDA/EMA and still are in infancy at the moment if we look at wider prospective and applications of nanomedicine. RESULTS: For a formulation scientist, it is much needed that well-explained and directive guidelines should be available before leading to the development of the generic versions of these nano-cargos. CONCLUSION: Here, in this review, we have summarized the silent features of the regulatory perspectives related to the nanotechnology based next generation therapeutics and diagnostics. AU - Paliwal, R.* AU - Kumar, P. AU - Chaurasiya, A.* AU - Kenwat, R.* AU - Katke, S.* AU - Paliwal, S.R.* C1 - 63649 C2 - 51740 SP - 165-177 TI - Development of nanomedicines and nano-similars: Recent advances in regulatory landscape. JO - Curr. Pharm. Des. VL - 28 IS - 2 PY - 2021 SN - 1381-6128 ER - TY - JOUR AB - Peptides and proteins are two classes of molecules with attractive possibilities for therapeutic applications. However, the bottleneck for the therapeutic application of many peptides and proteins is their short halflives in vivo, typically just a few minutes to hours. Half-life extension strategies have been extensively studied and many of them have been proven to be effective in the generation of long-acting therapeutics with improved pharmacokinetic and pharmacodynamic properties. In this review, we summarize the recent advances in half-life extension strategies, illustrate their potential applications and give some examples, highlighting the strategies that have been used in approved drugs and for drugs in clinical trials. Meanwhile, several novel strategies that are still in the process of discovery or at a preclinical stage are also introduced. In these strategies, the two most frequently used half-life extension methods are the reduction in the rate of renal clearance or the exploitation of the recycling mechanism of FcRn by binding to the albumin or IgG-Fc. Here, we discuss half-life extension strategies of recombinant therapeutic protein via genetic fusion, rather than chemical conjugation such as PEGylation. With the rapid development of genetic engineering and protein engineering, novel strategies for half-life extension have been emerged consistently. Some of these will be evaluated in clinical trials and may become viable alternatives to current strategies for making next-generation biodrugs. AU - Tan, H.* AU - Su, W.* AU - Zhang, W.* AU - Wang, P.* AU - Sattler, M. AU - Zou, P. C1 - 55892 C2 - 46628 SP - 4932-4946 TI - Recent advances in half-life extension strategies for therapeutic peptides and proteins. JO - Curr. Pharm. Des. VL - 24 IS - 41 PY - 2018 SN - 1381-6128 ER - TY - JOUR AB - The question what makes an allergen an allergen puzzled generations of researchers. Pollen grains of anemophilous plants are the most important allergen carriers in ambient air, and pollinosis is a highly prevalent multi-organ disease in civilized countries. In the past, research on the allergenicity of pollen has mainly focused on elucidating genetic predisposing factors and on defining certain structural characteristics of pollen derived allergens. Recently, studies extended to the analysis of non-allergenic, adjuvant mediators co-released from pollen. Besides active proteases and oxidases, extracts of pollen contain low molecular weight molecules like pollen-associated lipid mediators or adenosine exhibiting a potential to stimulate and modulate cultured human immune cells. This article reviews our current knowledge on non-allergenic, protein and non-protein compounds from pollen and their in vitro and in vivo effects on the allergic immune response. To ultimately judge the physiological relevance of these compounds, a systematic approach will be needed comparing their releasability, content and activity in different, allergenic and non-allergenic, pollen species. System biology such as proteome and metabolome analysis will be a useful future approach to better understand pollen biology. AU - Gilles, S. AU - Behrendt, H. AU - Ring, J.* AU - Traidl-Hoffmann, C. C1 - 8302 C2 - 30108 SP - 2314-2319 TI - The pollen enigma: Modulation of the allergic immune response by non-allergenic, pollen-derived compounds. JO - Curr. Pharm. Des. VL - 18 IS - 16 PB - Bentham Science PY - 2012 SN - 1381-6128 ER - TY - JOUR AU - Dietmann, S. AU - Aguilar, D. AU - Mader, M.T. AU - Oesterheld, M. AU - Ruepp, A. AU - Stuempflen, V. AU - Mewes, H.-W. C1 - 4913 C2 - 24029 SP - 3723-3734 TI - Resources and tools for investigating biomolecular networks in mammals. JO - Curr. Pharm. Des. VL - 12 PY - 2006 SN - 1381-6128 ER -